Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
ONCR Oncorus
0.436-0.014-3.11%
Close
02/03 16:00 ET
0.4360.0000.00%
Post Mkt Price 02/03 16:36 ET
High
0.470
Open
0.450
Turnover
190.31K
Low
0.420
Pre Close
0.450
Volume
425.67K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Oncorus Announces Research Collaboration With Daewoong Pharmaceutical for the Development of Lipid Nanoparticle Formulations for MRNA Drug Candidates
Research collaboration leverages Oncorus' proprietary ionizable amines, PEG lipids, LNP formulations, process development and manufacturing together with Daewoong's mRNA expertiseOpportunity for future license,
Oncorus, Inc. (NASDAQ:ONCR) Major Shareholder Sells $36,855.78 in Stock
Oncorus, Inc. (NASDAQ:ONCR – Get Rating) major shareholder James E. Flynn sold 141,753 shares of the stock in a transaction that occurred on Thursday, December 29th. The stock was sold at an average
Sawtooth Solutions LLC Cuts Stock Position in Oncorus, Inc. (NASDAQ:ONCR)
Sawtooth Solutions LLC lessened its stake in shares of Oncorus, Inc. (NASDAQ:ONCR – Get Rating) by 52.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exch
Oncorus, Inc. (NASDAQ:ONCR) Major Shareholder James E. Flynn Sells 99,718 Shares
Oncorus, Inc. (NASDAQ:ONCR – Get Rating) major shareholder James E. Flynn sold 99,718 shares of the business's stock in a transaction that occurred on Monday, December 19th. The shares were sold at a
Oncorus (NASDAQ:ONCR) Stock Rating Lowered by HC Wainwright
Oncorus (NASDAQ:ONCR – Get Rating) was downgraded by research analysts at HC Wainwright from a "buy" rating to a "neutral" rating in a research report issued to clients and investors on Tuesday, The
Oncorus Downgraded to Neutral From Buy at H.C. Wainwright
HC Wainwright & Co. Downgrades Oncorus to Neutral
HC Wainwright & Co. analyst Swayampakula Ramakanth downgrades Oncorus from Buy to Neutral.
Analyzing Oncorus (NASDAQ:ONCR) & Perrigo (NYSE:PRGO)
Oncorus (NASDAQ:ONCR – Get Rating) and Perrigo (NYSE:PRGO – Get Rating) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their p
Oncorus (NASDAQ:ONCR) Stock Rating Lowered by Piper Sandler
Piper Sandler cut shares of Oncorus (NASDAQ:ONCR – Get Rating) from an overweight rating to a neutral rating in a research report released on Wednesday, The Fly reports. Piper Sandler currently has $
Oncorus, Inc. (NASDAQ:ONCR) Short Interest Up 20.7% in November
Oncorus, Inc. (NASDAQ:ONCR – Get Rating) saw a large increase in short interest in the month of November. As of November 15th, there was short interest totalling 852,400 shares, an increase of 20.7%
Company Overview
More
Oncorus, Inc. engages in the research and development of a viral immunotherapy platform. It develops an immunotherapy platform to treat cancer such as oncolytic Herpes Simplex Virus Platform and Synthetic Virus Platform. The company was founded by Mitchell H. Finer, Joseph C. Glorioso III, Kenneth P. Greenberg, Cyrus D. Mozayeni, and Paola Grandi on April 1, 2015 and is headquartered in Andover, MA.
CEO： Dr. Theodore Ashburn, M.D.,PhD
Market： NASDAQ
Listing Date： 10/02/2020
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet